Pharmacelera and Welab Barcelona are announcing a research collaboration on providing drug discovery services

Barcelona, January 27th, 2023 – Pharmacelera, the leading provider of computational tools for hit discovery, and Welab, the leading drug discovery and development platform is Spain, have announced a partnership to jointly provide an efficient solution from hit finding up to pre-clinical development of new chemical entities.

Through this collaborative platform aiming to foster and encourage the discovery of new medicines for tomorrow, the two companies will be able to combine the expertise in virtual screening with the capability to synthesize and test the predicted molecules, both under the roof of their facilities at the Parc Científic of Barcelona.

The collaboration will provide integrated resources, expertise, and capabilities for speeding up new discoveries, and therapeutic opportunities to research groups from academy, biotech, or pharmaceutical industry.

Enric Gibert (Pharmacelera CEO and co-founder): “Through this partnership with a team of experienced drug discovery researchers from the Pharma industry, Pharmacelera will be able to offer an integrated service to its customers that will extend the in-silico design and identification of potential hits to their validation through synthesis, ADME profiling, and testing. Being the two companies located within the Parc Científic of Barcelona, the interactions during projects will be facilitated and our respective customers should get more value in getting results faster.”

Jose Miguel Vela (Welab CSO): “This collaboration with Pharmacelera will boost our capacity to provide new drug discovery programs to our customers. Beyond leveraging hit finding capabilities, the deep and complementary knowledge and expertise of both companies add high value to this partnership, for us, and for our clients”.

About Pharmacelera

Pharmacelera develops advanced computational tools for the discovery of novel hits using accurate Quantum-Mechanics (QM), Artificial Intelligence (AI), and High-Performance Computing (HPC). The company’s products PharmScreen® and PharmQSAR use 3D molecular descriptors derived from Quantum-Mechanics (QM) calculations to mine an unexplored chemical space and to identify hits uncovered by traditional algorithms. Pharmacelera is a private company founded in 2015 and based in Barcelona, Spain. The company works with several big pharma and biotech organizations across Europe and the United States.

About WeLab Barcelona

Founded in 2020 through the acquisition of the Drug Discovery & Preclinical Development center from Esteve Pharmaceuticals S.A., Welab Barcelona is formed by experienced scientists with cutting-edge equipment and technologies, and a proven track record across the entire drug discovery and development cycle, successfully translating new discoveries into medicines. Welab’s R&D site, located in the Parc Científic of Barcelona, is the largest integrated Drug Discovery Center in Spain, and provides Pharma R&D services and scientific solutions.


Media Contacts


Rémy Hoffmann, CBDO (

Welab Barcelona

Xavier Codony (




Torre R, 4a planta, Despatx A05, Parc Científic de Barcelona (PCB). C/ Baldiri Reixac 4-8 08028 Barcelona